Loss of the fructose transporter SLC2A5 inhibits cancer cell migration.

Autor:	Groenendyk J; Department of Biochemistry, University of Alberta, Edmonton, AB, Canada., Stoletov K; Department of Oncology, University of Alberta, Edmonton, AB, Canada., Paskevicius T; Department of Biochemistry, University of Alberta, Edmonton, AB, Canada., Li W; Department of Biochemistry, University of Alberta, Edmonton, AB, Canada., Dai N; Department of Biochemistry, University of Alberta, Edmonton, AB, Canada., Pujol M; Department of Biochemistry, University of Alberta, Edmonton, AB, Canada., Busaan E; Department of Biochemistry, University of Alberta, Edmonton, AB, Canada., Ng HH; Department of Biochemistry, University of Alberta, Edmonton, AB, Canada., Boukouris AE; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Saleme B; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Haromy A; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Cui K; Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China., Hu M; National '111' Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan, China., Yan Y; National '111' Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan, China., Zhang R; National '111' Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan, China., Michelakis E; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Chen XZ; Department of Physiology, University of Alberta, Edmonton, AB, Canada., Lewis JD; Department of Oncology, University of Alberta, Edmonton, AB, Canada., Tang J; National '111' Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan, China., Agellon LB; School of Human Nutrition, McGill University, Montreal, QC, Canada., Michalak M; Department of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Jazyk:	angličtina
Zdroj:	Frontiers in cell and developmental biology [Front Cell Dev Biol] 2022 Sep 30; Vol. 10, pp. 896297. Date of Electronic Publication: 2022 Sep 30 (Print Publication: 2022).
DOI:	10.3389/fcell.2022.896297
Abstrakt:	Metastasis is the primary cause of cancer patient death and the elevation of SLC2A5 gene expression is often observed in metastatic cancer cells. Here we evaluated the importance of SLC2A5 in cancer cell motility by silencing its gene. We discovered that CRISPR/Cas9-mediated inactivation of the SLC2A5 gene inhibited cancer cell proliferation and migration in vitro as well as metastases in vivo in several animal models. Moreover, SLC2A5-attenuated cancer cells exhibited dramatic alterations in mitochondrial architecture and localization, uncovering the importance of SLC2A5 in directing mitochondrial function for cancer cell motility and migration. The direct association of increased abundance of SLC2A5 in cancer cells with metastatic risk in several types of cancers identifies SLC2A5 as an important therapeutic target to reduce or prevent cancer metastasis. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Groenendyk, Stoletov, Paskevicius, Li, Dai, Pujol, Busaan, Ng, Boukouris, Saleme, Haromy, Cui, Hu, Yan, Zhang, Michelakis, Chen, Lewis, Tang, Agellon and Michalak.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu